计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| I648479-5mg |
5mg |
期货 ![]() |
| |
| I648479-10mg |
10mg |
期货 ![]() |
| |
| I648479-25mg |
25mg |
期货 ![]() |
| |
| I648479-50mg |
50mg |
期货 ![]() |
|
| 别名 | 磷酸英菲格拉替尼 |
|---|---|
| 英文别名 | N'-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-N-(6-(4-(4-ETHYLPIPERAZIN-1-YL)ANILINO)PYRIMIDIN-4-YL)-N-METHYLUREA PHOSPHATE (1:1) | 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea;phosphoric acid | NVP-BGJ3 |
| 规格或纯度 | ≥99% |
| 英文名称 | Infigratinib phosphate |
| 生化机理 | Infigratinib phosphate(BGJ-398 phosphate;NVP-BGJ398 phosphate)是 FGFR 家族的强效抑制剂,对 FGFR1、FGFR2、FGFR3 和 FGFR4 的 IC 50 分别为 0.9 nM、1.4 nM、1 nM 和 60 nM。 |
| 储存温度 | 2-8°C储存,干燥 |
| 运输条件 | 冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 成纤维细胞生长因子受体抑制剂 |
| 产品介绍 |
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC 50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1 , FGFR2 , FGFR3 , and FGFR4 , respectively. In Vitro Infigratinib phosphate inhibits FGFR1, FGFR2, and FGFR3 with IC 50 =~1 nM, FGFR3 K650E with IC 50 =4.9 nM, and FGFR4 with IC 50 =60 nM. IC 50 values for all other kinases are in the μM range (FYN, LCK, YES, and ABL, IC 50 =1.9, 2.5, 1.1, and 2.3 μM, respectively) except for VEGFR2, KIT, and LYN, which are inhibited at submicromolar concentrations (IC 50 =0.18, 0.75, and 0.3 μM, respectively). Infigratinib inhibits the proliferation of the FGFR1-, FGFR2-, and FGFR3-dependent BaF3 cells with IC 50 values which are in the low nanomolar range and comparable to those observed for the inhibition of the receptors kinase activity in the enzymatic assay. For the remaining cells, all IC 50 values are greater than 1.5 μM except for VEGFR2 (IC 50 1449 and 938 nM), for which there is at least a 400-fold selectivity versus FGFR1, FGFR2, and FGFR3. Infigratinib (ranging between 1 nM and 10 μM) is potent at inhibiting cell growth of FGFR2 -mutant endometrial cancer cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Infigratinib is administered to athymic nude mice implanted subcutaneously with RT112/luc1 tumors: either as a 5 mg/kg intravenous bolus in NMP/PEG200 (1:9, v/v) or orally by gavage as a suspension in PEG300/D5W (2:1, v/v) at a 20 mg/kg dose. The relevant pharmacokinetic (PK) parameters indicate that the oral bioavailability of Infigratinib in this study is 32%. After intravenous dosing, Infigratinib shows a rapid distribution from the vascular compartment into the peripheral tissues, translating into a high volume of distribution (26 L/kg). The plasma clearance is high at 3.3 L/h/kg (61% of liver blood flow). The ratio of tumor to plasma after oral dosing based on AUC is determined to be 10 . Infigratinib (30 mg/kg) significantly inhibits the growth of FGFR2 -mutated endometrial cancer xenograft models. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:FGFR1 0.9 nM (IC 50 ) FGFR2 1.4 nM (IC 50 ) FGFR3 1 nM (IC 50 ) FGFR4 60 nM (IC 50 ) |
| 纯度 | ≥99% |
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea;phosphoric acid |
| INCHI | 1S/C26H31Cl2N7O3.H3O4P/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28;1-5(2,3)4/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31);(H3,1,2,3,4) |
| InChi Key | GUQNHCGYHLSITB-UHFFFAOYSA-N |
| Smiles | CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl.OP(=O)(O)O |
| Isomeric SMILES | CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl.OP(=O)(O)O |
| 关联CAS | 1310746-10-1 |
| PubChem CID | 56669626 |
| 分子量 | 658.47 |
| 溶解性 | DMSO : ≥ 12.5 mg/mL (18.98 mM) |
|---|---|
| 分子量 | 658.500 g/mol |
| XLogP3 | |
| 氢键供体数Hydrogen Bond Donor Count | 5 |
| 氢键受体数Hydrogen Bond Acceptor Count | 12 |
| 可旋转键计数Rotatable Bond Count | 8 |
| 精确质量Exact Mass | 657.163 Da |
| 单同位素质量Monoisotopic Mass | 657.163 Da |
| 拓扑极表面积Topological Polar Surface Area | 173.000 Ų |
| 重原子数Heavy Atom Count | 43 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 773.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 2 |
¥720.90
¥368.90
¥576.72